The authors focused on the current surgical treatment of resectable gastric cancer, and
significance of peri-and post-operative chemo or chemoradiation. Gastric cancer is the 4 th …

Gastric cancer imposes a considerable health burden around the globe despite its declining
incidence. The disease is often diagnosed in advanced stages and is associated with a poor …

Background Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2)-
mediated signalling and angiogenesis can contribute to the pathogenesis and progression …

Background Almost half of people with esophageal or gastroesophageal junction cancer
have metastatic disease at the time of diagnosis. Chemotherapy and targeted therapies are …

Background: In preclinical gastric cancer (GC) models, FGFR2 amplification was associated
with increased tumour cell proliferation and survival, and drugs targeting this pathway are …

BACKGROUND: Gastric cancer remains a major health problem worldwide. Treatment of
advanced gastric cancer is controversial and there is no standard regimen for first-or second …

The development of molecular targeted therapeutics in oncology builds on many years of
scientific investigation into the cellular mechanics of malignant transformation and …

BACKGROUND The AKT inhibitor MK‐2206 at a dose of 60 mg every other day was
evaluated in gastric/gastroesophageal junction cancers. METHODS Patients who had …

No standard adjuvant or palliative chemotherapy regimen has been internationally
approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is …

It is increasingly recognized that gastric cancer is a heterogeneous disease which may be
divided into subgroups based on histological, anatomical, epidemiological and molecular …